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The pancreas secretes digestive proenzymes typically in their
monomeric form. A notable exception is the ternary complex
formed by proproteinase E, chymotrypsinogen C, and procar-
boxypeptidase A (proCPA) in cattle and other ruminants. In the
human and pig pancreas binary complexes of proCPAwith pro-
elastases were found. To characterize complex formation
among human pancreatic protease zymogens in a systematic
manner, we performed binding experiments using recombinant
proelastases CELA2A, CELA3A, and CELA3B; chymotrypsino-
gens CTRB1, CTRB2, CTRC, and CTRL1; and procarboxypep-
tidases CPA1, CPA2, and CPB1. We found that proCELA3B
bound not only to proCPA1 (KD 43 nM) but evenmore tightly to
proCPA2 (KD 18 nM), whereas proCELA2A bound weakly to
proCPA1 only (KD 152 nM). Surprisingly, proCELA3A, which
shares 92% identity with proCELA3B, did not form stable com-
plexes due to the evolutionary replacement of Ala241 with Gly.
The polymorphic nature of position 241 in both CELA3A (4%
Ala241 alleles) and CELA3B (2% Gly241 alleles) points to indi-
vidual variations in complex formation. The functional effect of
complex formationwas delayed procarboxypeptidase activation
due to increased affinity of the inhibitory activation peptide,
whereas proelastase activation was unchanged. We conclude
that complex formation among human pancreatic protease
zymogens is limited to a subset of proelastases and procarboxy-
peptidases. Complex formation stabilizes the inhibitory activa-
tion peptide of procarboxypeptidases and thereby increases
zymogen stability and controls activation.
The exocrine pancreas produces digestive enzymes includ-
ing serine- andmetalloproteases secreted as inactive precursors
(zymogens) that attain their active form in the duodenum.
Physiological activation of protease zymogens is initiated by
enteropeptidase-mediated activation of trypsinogen to trypsin
followed by trypsin-mediated activation of chymotrypsinogens,
proelastases, and procarboxypeptidases (1). Full activation
of human procarboxypeptidases A1 (proCPA1)2 and A2
(proCPA2) requires additional cleavages by chymotrypsin C
(CTRC) to facilitate dissociation of the inhibitory activation
peptide (2). Renewed interest in digestive protease physiology
was spurred by the recognition that mutations in cationic tryp-
sinogen (PRSS1), the pancreatic secretory trypsin inhibitor
(SPINK1), CTRC and CPA1 are strongly associated with
chronic pancreatitis in humans (3–6). At the same time, infor-
mation obtained from genome and pancreatic transcriptome
sequencing allowed correct annotation of the full complement
of digestive protease isoforms and opened up avenues for inves-
tigations using genetically-defined recombinant enzymes.
These studies, in turn, led to novel insight into digestive prote-
ase function such as the central role of CTRC in the regulation
of human trypsinogen (7–9) and procarboxypeptidase activa-
tion (2), the role of mesotrypsin (PRSS3) in degrading trypsin
inhibitors (10, 11), and the significance of mutation-induced
digestive protease misfolding in acinar cell stress and chronic
pancreatitis (6, 12, 13).
A long known yet still unsolved enigma in digestive protease
biochemistry is the physiological function of complex forma-
tion. Althoughmost zymogens are secreted in theirmonomeric
forms, ternary and binary complexes have also been identified
(for reviews, see Refs. 14–17). The best studied example is the
bovine ternary complex formed by proCPA (subunit I), chy-
motrypsinogen C (subunit II), and proproteinase E (subunit
III), the ortholog of human chymotrypsin-like proelastases 3A
and 3B (proCELA3AandproCELA3B) (18–23). Similar ternary
complexes were found in other ruminants such as goat and
sheep (24). Bovine ternary complexes isolated in earlier studies
all contained an autolyzed, inactive form of proproteinase E,
cleaved at the Val30-Asn31 peptide bond (25). This truncated
proelastase was later shown to be a purification artifact due to
the catalytic action of trace amounts of active elastase (26–28).
In addition to the ternary complex, the bovine pancreas also
contains lower levels of binary complexes of proCPA with chy-
motrypsinogen C (29) or proproteinase E (30). In contrast, the
pig and human pancreas secretes binary complexes only,
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formed by proCPA and proproteinase E in the pig (31–33), and
proCPA1 and proCELA3B or proCELA2A in humans (34–36).
Interestingly, a relatively poorly characterized complex
between proCPA2 and chymotrypsinogen B (CTRB) was also
described in the rat pancreas (37). Finally, proCPA of the sei
whale was found in complex with an unidentified protein, pos-
sibly chymotrypsinogen C (38).
The bovine ternary complex has been crystallized and its
structure has been solved (39, 40). In this complex chymo-
trypsinogen C and proproteinase E are bound to different sur-
faces of the centrally located proCPA. The activation peptide of
proCPA participates in most of the binding interactions, sug-
gesting that the rate of proCPA activation might be affected by
complex formation and that the complex should dissociate
upon proCPA activation (41). In contrast, the activation pep-
tides of chymotrypsinogen C and proproteinase E are not
involved in binding contacts; therefore, activation of these
zymogens should not be affected in the complex. Earlier func-
tional studies using the chemically dissociated pig binary com-
plex demonstrated small differences in the rate of trypsin-me-
diated proCPA activation, which was inconsistent with
experimental observations using components of the bovine ter-
nary complex (23, 32, 33). This discrepancy has not been
resolved and the exact effect of complex formation on proCPA
activation has remained uncertain.
Even though the physiological role of ternary and binary
complexes formed by pancreatic protease zymogens has
remained perplexing, investigations into this problem dwin-
dled before the advent of the genomic era. Therefore, the objec-
tive of the present study was to perform a comprehensive anal-
ysis of complex formation among human pancreatic protease
zymogens using recombinant proenzymes and to characterize
the binding affinities and the functional significance of the
complexes.
Results
Protease Zymogens Studied—There are three human pancre-
atic procarboxypeptidases encoded by the CPA1, CPA2, and
CPB1 genes. Four genes code for chymotrypsinogens (CTRB1,
CTRB2, CTRC, and CTRL1) and five genes for chymotrypsin-
like proelastases (CELA1, CELA2A, CELA2B, CELA3A, and
CELA3B). TheCELA1 gene, which is the ortholog of the classic
pig elastase, is not expressed in the human pancreas due to
evolutionary mutations in its promoter region (42, 43); there-
fore, this isoform was not studied here. As their gene symbols
suggest, both CELA2A-CELA2B and CELA3A-CELA3B gene
pairs represent gene duplications in humans. CELA2B was also
excluded from the present study as this protein has never been
demonstrated in pancreatic secretions and the recombinantly
expressed enzyme is inactive due to multiple evolutionary
mutations (44). In contrast, both CELA3A and CELA3B are
expressed in the human pancreas and their concentrations
appear comparable at the mRNA and protein levels (45, 46).
Finally, the three human trypsinogens encoded by the PRSS1,
PRSS2, and PRSS3 genes were not included as trypsinogens
studied so far have been always found monomeric (1).
Autolysis of ProCELA3A and ProCELA3B—Subunit III of the
bovine ternary complex was originally identified as an inactive
elastase cleaved at the Val30-Asn31 peptide bond (Ref. 25 and
references therein). A similar defective elastase was detected in
binary complexes with proCPA1 from human pancreas (34).
Subsequent studies revealed that subunit III was a purification
artifact resulting from the autolytic cleavage of proproteinase E
by small amounts of active proteinase E (26–28).We found that
despite every precaution to prevent trypsin contamination, our
freshly made proCELA3B preparations were already partially
autolyzed. As judged by N-terminal Edman degradation, typi-
cally about 60% of the fresh proCELA3B preparations were
intact, and the rest showed cleavages at the Ser26-Ser27 (20%)
and Val30-Asn31 (20%) peptide bonds (Fig. 1). In contrast, fresh
proCELA3A preparations were uncleaved. Autolysis occurred
during the purification procedure as proCELA3B in the condi-
tioned medium of transfected cells was found intact. During
storage at 4 °C, autolysis proceeded slowly with about 80% of
proCELA3B cleaved in 6 weeks, with the predominant cleavage
(55–60%) observed at the Val30-Asn31 peptide bond. In the
same time period, preparations of proCELA3A also became
partially cleaved at the Ser25-Ser26 (10%), Ser27-Arg28 (10%),
and Val30-His31 (3%) peptide bonds. Surprisingly, when the
tryptic activation site Arg28 was mutated in proCELA3B to His
(R28H mutant), the fresh zymogen preparations were even
more autolyzed (55% cleaved)with enhanced cleavage observed
at the Ser26-Ser27 peptide bond (40%). The behavior of the
R28H mutant indicated that autolytic cleavage was more likely
to occur as a result of the intrinsic zymogen activity of
proCELA3B rather than through inadvertent proelastase acti-
vation by trypsin contamination. As expected, mutation of the
catalytic Ser in proCELA3B (S217A mutant) yielded zymogen
preparations with intact N termini. Therefore, for the quanti-
tative binding experiments discussed below we used the S217A
mutant versions of proCELA3A and proCELA3B constructs.
Binding of Human Proelastases and Chymotrypsinogens to
Procarboxypeptidases—To develop a simple screening assay for
binding among various pancreatic protease zymogens, we took
advantage of the availability of His-tagged and non-tagged
expression constructs in our laboratory. We expressed all
proenzymes in HEK 293T cells via transient transfection and
mixed the conditioned media in different combinations of His-
tagged and non-tagged zymogens. After a brief incubation to
allow for binding, the mixture was passed through a nickel col-
FIGURE 1.Autolytic cleavage sites in the activation peptide and N-termi-
nal region of human proCELA3A and proCELA3B. The activation peptides
(Tyr18-Arg28) are highlighted in gray. The activation site Arg28 is emboldened.
See text for details.
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umn; the columnwas washed with 20mM imidazole and bound
proteins were eluted with 250 mM imidazole. Four 0.5-ml frac-
tions were collected and analyzed by SDS-PAGE and Coomas-
sie Blue staining (Fig. 2). In the absence of binding, only the
His-tagged zymogen was eluted, whereas complex formation
resulted in co-elution of the non-tagged binding partner aswell.
We tested for potential binary complexes between non-tagged
procarboxypeptidases (proCPA1, proCPA2, and proCPB1) and
His-tagged proelastases (proCELA2A, proCELA3A, and
proCELA3B) and chymotrypsinogens (CTRB1, CTRB2, CTRC,
and CTRL1). As shown in Fig. 2, binding was detected between
proCELA2A and proCPA1, proCELA3B and proCPA1, and
proCELA3B and proCPA2, whereas other zymogen combina-
tions did not result in measurable complex formation (data not
shown for CTRB1, CTRB2, and CTRL1). The observation that
proCPA2 formed a complex with human proCELA3B was
novel, whereas complexes of proCELA3B and proCELA2A
with proCPA1 were previously reported (34–36). The inability
of proCELA3A to bind to procarboxypeptidases was surprising
as this isoform is 92% identical to proCELA3B at the amino acid
level.We also exploredwhether the CTRC zymogenmight par-
ticipate in ternary complexes with proCELA3B and proCPA1
or proCPA2. Non-tagged CTRC proenzyme was mixed with
His-tagged proCELA3B andnon-tagged proCPA1or proCPA2.
FIGURE 2. Binary complex formation of human pancreatic protease zymogens. Qualitative binding assays using His-tagged proelastases (proCELA,
includingproCELA2A, proCELA3A, andproCELA3B), His-tagged chymotrypsinogens (CTRB1, CTRB2, CTRC, andCTRL1), andnon-taggedprocarboxypeptidases
(proCP, including proCPA1, proCPA2, and proCPB1) were performed as described under ”Experimental Procedures.“ The numbers above the lanes indicate the
fractions collected after elution from the nickel column. None of the chymotrypsinogens formed complexes; representative negative results are shown for the
CTRC zymogen only. Representative gel pictures of two binding experiments are shown.
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Because CTRC and proCELA3B migrate similarly on SDS-
PAGE, the nickel column eluate was analyzed for the presence
of CTRC byWestern blots. No detectable CTRC zymogen was
co-eluted with the proCELA3B-proCPA1 or proCELA3B-
proCPA2 complexes (not shown).
Quantitative Binding Experiments with Purified Proelastases
and Procarboxypeptidases—To characterize binding affinity
between various human procarboxypeptidases and proelasta-
ses, we developed an equilibrium binding assay in which a fixed
concentration of non-tagged proCPA1 (250 nM) and proCPA2
(100 nM) was incubated with increasing concentrations of His-
tagged proelastases (0–1500 nM) in the presence of nickel resin.
After 15min incubation, His-tagged proelastases together with
bound procarboxypeptidases were removed by centrifugation.
The amount of the free (unbound) proCPA1 and proCPA2
remaining in the supernatant was determined by enzyme activ-
ity measurements and free proCPA1 and proCPA2 concentra-
tions were plotted as a function of total proelastase concentra-
tions. The equilibrium dissociation constants (KD) were
determined by fitting the data points to the simple reversible
binding equation, as described under “Experimental Proce-
dures.” As shown in Fig. 3, proCELA3Bbound to both proCPA1
and proCPA2 with relatively high affinity, as judged by the KD
values of 43 2 and 18 1 nM, respectively. The slightly stron-
ger binding observed with proCPA2 was surprising as a
proCELA3B-proCPA2 complex has not been identified before
in human pancreatic secretions. In contrast, only minimal
binding of proCELA3A to proCPA1 and proCPA2was detected
with KD values estimated at 10.9 1 and 7.1 0.2 M, respec-
tively (Fig. 4). Thus, proCELA3A and proCELA3B exhibit at
least 250- and 400-fold differences in binding affinity to
proCPA1 and proCPA2, respectively. In agreement with a
report of a proCELA2A-proCPA1 complex found in human
pancreatic juice, we measured binding of proCELA2A to
proCPA1 with a KD value of 152  22 nM; which was about
4-fold weaker than binding of proCELA3B (Fig. 4). In contrast,
proCELA2A bound to proCPA2A at least 33-fold weaker, with
an estimated KD of 4.2 0.4 M.
Evolutionary Replacement of Ala241 with Gly in ProCELA3A
Caused Loss of Binding to Procarboxypeptidases—Proelastases
CELA3A and CELA3B exhibit 92% identity at the amino acid
level yet only proCELA3B formed tight complexes with procar-
boxypeptidases. We mapped the differences between the two
proleastases to the binding interface between bovine subunit III
(proproteinase E) and proCPA in the published structure of the
ternary complex (Fig. 5A). We found five amino acid differ-
ences between proCELA3A and proCELA3B at positions 77,
78, 79, 197, and 241, which could potentially affect binding. To
test the significance of these evolutionary changes, we replaced
these amino acids in proCELA3B with the corresponding
residues from proCELA3A resulting in triple mutant
S77R,S78D,W79L and singlemutants S197T andA241G.Qual-
itative binding experiments indicated that mutation A241G
had the most drastic effect as it essentially abolished binding,
whereas slightly decreased binding was observedwith the triple
mutant and essentially unchanged binding with mutant S197T
(Fig. 5B). When binding of proCELA3B mutant A241G was
measured in a quantitative manner, KD values of 2.2 0.1 and
1.0  0.03 M were determined against proCPA1 and
proCPA2, respectively, indicating a more than 50-fold
decreased affinity (Fig. 6). Still, compared with proCELA3A,
binding of proCELA3B mutant A241G to proCPA1 and
proCPA2 was at least 5- and 7-fold stronger, respectively, indi-
cating that additional changes in proCELA3A contribute to the
overall loss of affinity. Therefore, we measured binding of the
S77R,S78D,W79L triple mutant to proCPA1 and proCPA2 and
found KD values of 81  5 and 130  7 nM, respectively, indi-
cating2- and 7-fold reduced affinity, respectively, relative to
wild-type proCELA3B (reviewed but not shown). Taken
together, we can conclude that the major determinant for the
defective binding of proCELA3A to procarboxypeptidases is
the evolutionary change of Ala241 to Gly. This conclusion was
further supported by qualitative binding experiments using the
G241A proCELA3A mutant, which exhibited improved bind-
ing, particularly to proCPA1, relative to wild-type proCELA3A
FIGURE 3.Binding of proCELA3B to proCPA1 (A) and proCPA2 (B). Equilib-
riumbinding assays using purified proenzymeswere carried out as described
under ”Experimental Procedures.“ The free (unbound) proCPA concentra-
tions were plotted as a function of the total proCELA3B concentration. Data
points represent the average of three replicates  S.E. Error bars may be
smaller than symbol sizes. Data were fitted globally, the KD values and the
error of the fits are indicated. The catalytically inactive S217A mutant of
proCELA3B was used.
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(Fig. 5C). Quantitative binding experiments confirmed the
higher affinity of the proCELA3A G241A mutant toward
proCPA1 (KD 270 13 nM) and also to proCPA2 (KD 2.2 0.1
M), indicating 40- and 3.2-fold increased binding, respectively
(Fig. 6).
Complex Formation of Natural CELA3A and CELA3B Vari-
ants with Procarboxypeptidases—To identify relatively com-
mon CELA3A and CELA3B variants in the general population,
we queried the Exome Variant Server database of the NHLBI
Exome Sequencing Project. Table 1 lists the coding sequence
(exonic) variants that were found to occur with an allele fre-
quency higher than 1%.When the variants weremapped on the
structure of the bovine ternary complex, only CELA3B variants
W79R and A241G and CELA3A variant G241A were found at
or near the binding interface with proCPA. As described above,
variant A241G diminished binding of proCELA3B to proCPA1
and proCPA2 by more than 50-fold, and, conversely, variant
G214A increased binding of proCELA3A to proCPA1 by
40-fold and to proCPA2 by 3.2-fold (see Fig. 6). Because posi-
tion 241 is a major determinant of proelastase binding to
proCPA, the polymorphic nature of this amino acid points to
individual variability of complex formation in human pancre-
atic secretions.On the other hand, variantW79Rhad aminimal
effect on proCELA3B binding to proCPA1 or proCPA2; KD
values of 53  2 and 31  1 nM were measured, respectively
(Fig. 6).
Complex Formation Reduces the Rate of Procarboxypeptidase
Activation—Because the activation peptide of procarboxypep-
tidases is involved in binding to proCELA3B, activation kinetics
of proCPA1 and proCPA2 in complex are expected to be
delayed relative to their monomeric forms. Activation of
human proCPA1 and proCPA2 requires an initial cleavage at
the C terminus of the activation peptide by trypsin, which
results in the appearance of 10–15% of the full carboxypepti-
dase activity as the inhibitory activation peptide remains
attached (2). Subsequently, CTRC cleaves the severed activa-
tion peptide at multiple sites and facilitates its dissociation
resulting in full carboxypeptidase activity (2). We found that
both activation steps were affected by complex formation.
FIGURE 4. Binding of proCELA2A and proCELA3A to proCPA1 (A) and
proCPA2 (B). Equilibrium binding assays using purified proenzymes were
carried out as described in the legend to Fig. 3 and under ”Experimental
Procedures.“ See text for the error of the fits. For comparison, bindingdata for
wild-type proCELA3B from Fig. 3 are also indicated. Note that KD values in the
micromolar range should be considered estimates. The catalytically inactive
S217A mutant of proCELA3A was used. FIGURE 5. Structural determinants of defective proCELA3A binding to
proCPA1 and proCPA2. A, the positions of amino acid differences between
proCELA3A and proCELA3B were mapped to the binding interface between
bovine proCPA and proproteinase E. For clarity, chymotrypsinogen C was
omitted from the ternary complex (Protein Data Bank file 1PYT). Amino acid
residues at or near the interface are indicated. B, binding of proCELA3B triple
mutant S77R,S78D,W79L and single mutants S197T and A241G to proCPA1
and proCPA2. C, binding of proCELA3A mutant G241A to proCPA1 and
proCPA2.Qualitativebindingexperiments using conditionedmediawithHis-
taggedproelastases andnon-taggedprocarboxypeptidaseswere carried out
as described under ”Experimental Procedures.“ The numbers above the lanes
indicate the fractions eluted from the nickel column. Representative gel pic-
tures of two experiments are shown.
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When activation of 200 nM proCPA1 and proCPA2 was initi-
ated with 5 nM trypsin, only low levels of carboxypeptidase
activity developed, which was reduced by about 50% as a result
of complex formation with 2 M proCELA3B (Fig. 7). Because
trypsin also activates proCELA3B and elastase can partially
activate proCPA1 and proCPA2, in these experiments we used
the catalytically inactive S217A proCELA3B mutant, thereby
excluding this confounding factor. Addition of 5 nM CTRC to
the trypsin-cleaved proCPA1 or proCPA2 resulted in rapid
development of carboxypeptidase activity and the presence of 2
M proCELA3B reduced rates of activation by2- and 5-fold,
respectively (Fig. 7). The stronger effect observed with
proCPA2 is consistent with its somewhat tighter binding
to proCELA3B (see Fig. 3). Importantly, the low-affinity
proCELA3B mutant A241G had no effect whatsoever on
proCPA1 activation and had only a small effect on proCPA2
activation, confirming that the observed differences in activa-
tion rates were related to complex formation between the pro-
tease zymogens.
Complex Formation Has No Effect on Proelastase Activation
or Zymogen Activity—Activation of proCELA3B (150 nM) by
trypsin (2.5 nM)was unchangedwhen performed in the absence
or presence of 600 nM proCPA1 or proCPA2 (reviewed but not
shown). This finding is consistent with previous observations
on the pig binary complex (33). To evaluate whether binding of
proCELA3B to procarboxypeptidases alters the intrinsic zymo-
gen activity of the proelastase, we used the non-activable R28H
proCELA3B (500 nM)mutant andmeasured cleavage of a chro-
mogenic peptide substrate in the absence and presence of 500
nM proCPA1. No differences were found (reviewed but not
shown).
Complex Formation Stabilizes Binding of the Inhibitory Acti-
vation Peptide of Procarboxypeptidases—The activation pep-
tides of proCPA1 and proCPA2 act as tight-binding tethered
inhibitors (15–17). After cleavage with trypsin, the activation
FIGURE 6. Binding of proCELA3A variant G241A and proCELA3B variants
W79R and A241G to proCPA1 (A) and proCPA2 (B). Equilibrium binding
assays usingpurified proenzymeswere carried out as described in the legend
to Fig. 3 and under ”Experimental Procedures.“ For comparison, binding data
forwild-typeproCELA3AandproCELA3B fromFigs. 3 and4 are also indicated.
Data points represent the average of three replicates S.E. Error barsmay be
smaller than symbol sizes. See text for the error of the fits. Note that KD values
in themicromolar range shouldbe consideredestimates. TheproCELA3Aand
proCELA3B constructs used contained the S217A catalytic mutation.
TABLE 1
Genetic variants of CELA3A and CELA3B in the population
Data were taken from the Exome Variant Server of the National Heart, Lung, and
Blood Institute (NHLBI) Exome Sequencing Project. Only variants with a combined
allele frequency exceeding 1%were listed. The number of European-American (EA)
andAfrican-American (AA) alleles sequenced were 8600 and 4394 forCELA3A and
8600 and 4406 forCELA3B, respectively. Note that the genomic reference sequence
(chromosome 1 primary assembly) forCELA3A contains theG241A variant and the
reference sequence forCELA3B contains theW79R variant. Here we used the com-
mon alleles as reference (corresponding to the chromosome 1 alternate assembly)
and indicated the minor alleles as changes at these positions.
cDNA
change
Amino acid
change
EA
alleles
AA
alleles
All
alleles
CELA3A
c.722GC G241A 2.4% 7.9% 4.3%
CELA3B
c.235TC W79R 0.8% 14.3% 5.4%
c.401AT Q134L 0.1% 4.0% 1.4%
c.625AG I209V 3.2% 0.5% 2.3%
c.629GA R210H 1.6% 5.8% 3.0%
c.722CG A241G 1.7% 1.8% 1.7%
FIGURE 7. Effect of wild-type proCELA3B and mutant A241G on the acti-
vation of proCPA1 (A) and proCPA2 (B) by trypsin and CTRC. Procarboxy-
peptidases at 200 nM concentration were incubated at 37 °C in the absence
(control) or presence of 2 M wild-type proCELA3B or A241Gmutant in 0.1 M
Tris-HCl (pH 8.0), 1 mM CaCl2, and 0.05% Tween 20 (final concentrations) in
200 l final volume. Where indicated by arrows, 5 nM human cationic trypsin
and 5 nM human CTRC were added. At given times, 8- (CPA1) or 15-l (CPA2)
aliquots were withdrawn and carboxypeptidase activity was measured as
described under ”Experimental Procedures.“ Data points represent the aver-
age of three replicates S.E. Error barsmay be smaller than symbol sizes. The
catalytically inactive S217A mutants of proCELA3B and proCELA3B A241G
were used.
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peptides remain bound to the enzymes with slightly weakened
affinity resulting in the appearance of low levels of carboxypep-
tidase activity (2). The activity versus concentration plots of
trypsin-cleaved proCPA1 and proCPA2 follow a square root
function; in agreement with the law of mass action (Fig. 8).
From these plots we derivedKD values of 5.2 0.1 and 6.8 0.4
nM for proCPA1 and proCPA2, respectively. These updated
values are somewhat higher than those previously reported (0.8
nM) but still lie in the lownanomolar range (2).When the exper-
iments were repeated in the presence of 500 nM proCELA3B
(S217A mutant), we found that complex formation resulted in
higher affinity binding of the activation peptides. Thus, KD val-
ues of 1.4  0.1 nM were measured for both proCPA1 and
proCPA2 complexes, indicating a 4–5-fold increase in binding
affinity (Fig. 8). In contrast, 500 nM of the weakly binding
A241G proCELA3B (S217A) mutant had only a minimal (1.2-
fold) effect on the affinity of the proCPA1 and proCPA2 activa-
tion peptides, as judged by theKD values obtained: 4.2 0.1 nM
and 5.4  0.2 nM, respectively (Fig. 8). We conclude that the
likely physiological role of complex formation is stabilization of
procarboxypeptidase zymogens by increasing the affinity of
their inhibitory activation peptides.
Discussion
Complex formation of mammalian pancreatic procarboxy-
peptidases with proelastases and chymotrypsinogen C was
intensely researched in the pre-genomic era. These investiga-
tions identified ternary complexes in ruminants and binary
complexes in humans and pigs. The physiological significance
of complex formation has never been solved, although coordi-
nation of zymogen activation seemed a plausible possibility
(14–17). Our interest turned to these older studies when we
identified that loss-of-function CPA1 mutations increased risk
for chronic pancreatitis in children and we were searching for
possible mechanisms to explain pathogenesis (6). We realized
that complex formation among pancreatic protease zymogens
has never been studied using post-genomic era tools. Today the
full complement of digestive proteases, including all isoforms,
expressed by the human pancreas has been characterized at the
genomic and transcriptomic levels, which sets the stage for
recombinant expression of genetically defined proteins and
comprehensive, systematic studies at the protein level.
Using qualitative and quantitative binding assays we con-
firmed that human proCELA3B and, to a lesser degree,
proCELA2A bind to proCPA1, and made the new observation
that proCELA3B also binds to proCPA2. No other complex
formation was observed among human proelastases, chymo-
trypsinogens, and procarboxypeptidases. KD values for
proCELA3B bindingwere in the20–40 nM range, with stron-
ger binding to proCPA2, whereas proCELA2A showed weaker
affinity (KD 150 nM). A previous study measured binding
affinities for the dissociated components of the bovine ternary
complex and found that subunit III (proproteinase E) bound to
the binary complex of proCPA and chymotrypsinogen Cwith a
KD value of 160 nM,which, considering the different species and
methodology used, seems to be in reasonable agreement with
our results (47). The higher affinity of proCELA3B toward
proCPA2 versus proCPA1 was an unexpected observation
because this complex has never been isolated from human pan-
creatic juice so far. In fact, the seminal study by Pascual et al.
(35), which chromatographically resolved all forms of human
procarboxypeptidases, found only monomeric proCPA2. Why
this complex escaped detection so far is not readily apparent
but it may be related to the protein extraction methods used or
some peculiar chromatographic behavior. We also note that
proCPA1 is more abundant than proCPA2 in humans (see Fig.
1 in (48)), therefore, proCPA1 complexes may be more easily
isolated.
The gene encoding the ortholog of the bovine and pig pro-
proteinase E had duplicated in humans giving rise to the
CELA3A and CELA3B genes, which encode proelastases that
are 92% identical in their primary structure. Despite the high
degree of identity, proCELA3Abound to procarboxypeptidases
at least 250–400-fold weaker than proCELA3B. The major
determinant of the affinity loss was the Ala241 to Gly evolution-
ary change in CELA3A relative to CELA3B, which weakened
bindingmore than 50-fold. Inspection of the crystal structure of
FIGURE 8. Effect of wild-type proCELA3B andmutant A241G on the bind-
ingof the inhibitoryactivationpeptidesofproCPA1 (A) andproCPA2 (B).
Procarboxypeptidases were incubated at 2 M concentration with 50 nM
human cationic trypsin at 37 °C in 0.1 M Tris-HCl (pH 8.0), 15 mM NaCl, 1 mM
CaCl2, and 0.05% Tween 20 (final concentrations) in 100l final volume. After
30 min incubation, activated proenzymes were diluted to the indicated con-
centrations in 100 l final volume with assay buffer (0.1 M Tris-HCl (pH 8.0),
150 mM NaCl, 1 mM CaCl2, and 0.05% Tween 20) and incubated for 10 min at
22 °C in the absence (control) or presence of 500 nM wild-type proCELA3B or
A241G mutant. Carboxypeptidase activity was then measured by adding 10
l of N-[4-methoxyphenylazoformyl]-L-phenylalanine substrate to 60 M
final concentration, as described under ”Experimental Procedures.“ Carboxy-
peptidase activities were converted to free CPA1/CPA2 concentrations by
dividing the activity values with the slope of the linear concentration-activity
plots of CPA1/CPA2 fully activated with trypsin plus CTRC (see supplemental
Fig. S1 in Ref. 2). Data points represent the average of three replicates S.E.
Error bars may be smaller than symbol sizes. Data points were fitted to the
equation: y (K sqrt(K∧2 4Kx))/2, where K is the equilibrium dissocia-
tion constant. The variable x is the total concentration of trypsin-activated
proCPA1/proCPA2 present in the reaction and y is the concentration of free
CPA1/CPA2 in equilibrium. The catalytically inactive S217A mutants of
proCELA3B and proCELA3B A241G were used.
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the bovine ternary complex indicates that replacement of
Ala241 with Gly would result in the loss of a hydrophobic con-
tact between the side chain methyl group of Ala and the aro-
matic phenyl ring of Phe78 in proCPA1. In addition, the Gly
substitution may cause local changes in conformation thereby
compromising additional interactions. Interestingly, position
241 is polymorphic in a small percentage of the population;
both CELA3A G241A and CELA3B A241G variants have been
identified (see Table 1). These polymorphic forms are expected
to cause individual variations in procarboxypeptidase binding
in heterozygous carriers and offer a unique opportunity to
investigate the significance of complex formation in different
gastrointestinal diseases (e.g. pancreatitis) using genetic associ-
ation studies. These variations also suggest that complex for-
mation and zymogen activation do not need to be tightly regu-
lated for normal digestive physiology.
The physiological function of complex formation has puz-
zled researchers since the 1960s (see reviews in Refs. 14–17).
The crystal structure of the bovine ternary complex suggests
that proCPA activation should be delayed as the binding part-
ners shield the proCPA activation peptide (39–40). Comparing
chemically dissociated and re-associated bovine and porcine
complexes, earlier studies found relatively small and somewhat
conflicting differences in the rate and extent of procarboxypep-
tidase activation between monomeric and complexed proen-
zymes (23, 32, 33). In the pig binary complex, which probably
resembles the human situation more closely, the initial rate of
proCPA activation by trypsin was slower relative to the mono-
meric enzyme (33). As expected, activation of pig proproteinase
E was unaffected by complex formation (33).We recently dem-
onstrated that in the activation of human proCPA1 and
proCPA2 trypsin-mediated cleavage serves only as the initiat-
ing step and needs to be followed by CTRC-mediated cleavages
of the activation peptide (2). In our experiments presented here
we studied these two steps in the activation process separately.
We found that binding of proCELA3B decreased the initial car-
boxypeptidase activity generated by trypsin and subsequent
addition of CTRC to the trypsin-cleaved procarboxypeptidases
resulted in slower development of full carboxypeptidase activ-
ity from the complex versus the monomeric proenzyme. More
importantly, we demonstrated that binding of proCELA3B to
the inhibitory activation peptide of proCPA1 and proCPA2
increased its affinity toward theCPA1 andCPA2 enzymes. This
finding strongly suggests that a physiological role of complex
formation is the stabilization of the proCPA1 and proCPA2
zymogens and it also explains the less efficient activation of the
complexes by trypsin andCTRC.On the other hand, the intrin-
sic zymogen activity and trypsin-mediated activation of human
proCELA3B are unaffected by complex formation.
In summary, using recombinant proenzymes free of contam-
inating proteases we characterized binding of human proleas-
tases to procarboxypeptidases. Novel findings include the
observations that proCELA3B binds not only to proCPA1 but
also to proCPA2 and proCELA3A does not form complexes
largely due to the evolutionary replacement of Ala241 with Gly.
Complex formation increases binding affinity of the inhibitory
activation peptide of procarboxypeptidases and thereby stabi-
lizes the zymogen state and hinders activation.
Experimental Procedures
Nomenclature—Amino acid residues were numbered start-
ing with the initiator methionine of the primary translation
product; according to the recommendations of the Human
GenomeVariation Society. The official gene symbols were used
to denote human pancreatic proteases with a “pro” prefix to
indicate the zymogen form. Note that the ELA (elastase) gene
symbol has been recently changed to CELA (chymotrypsin-like
elastase).TheCELA3AandCELA3Bgenomicreferencesequences
on chromosome 1 (primary assembly, NC_000001.11) contain
theG241A andW79R variants, respectively (see Table 1). Thus,
these reference sequences represent polymorphic minor
alleles. The reference sequences in the alternate assembly
(NC_018912.2) correspond to the common alleles with respect
to these two positions. To be consistent with published litera-
ture, we kept the historical proproteinase E designation for the
bovine and porcine orthologs of human proCELA3A and
proCELA3B.
Plasmid Construction and Mutagenesis—Construction of
expression plasmids for human CELA3A, CELA3B, CTRC,
CTRB1, CTRB2, CTRL1, CPA1, CPA2, and CPB1 in the
pcDNA3.1() vector was described previously (2, 6, 8, 9, 49,
50). C-terminal His10 tags were engineered to the proelastase
and chymotrypsinogen expression plasmids using gene synthe-
sis (GenScript, Piscataway, NJ). Because the C-terminal amino
acid of CELA3A and CELA3B is His, the added tag contained
nine His residues. The coding DNA for human CELA2A with a
C-terminal His10 tag was custom synthesized (GenScript)
according to the sequence of IMAGE clone 6226278 (Gen-
BankTM CA952548) and cloned into pcDNA3.1() using XhoI
and BamHI restriction sites. Mutations were introduced by
overlap extension PCR mutagenesis.
Expression and Purification of Human Pancreatic Protease
Precursors—All protease zymogens were expressed in HEK
293T cells via transient transfection and purified from the con-
ditioned medium. HEK 293T cells were grown in Dulbecco’s
modified Eagle’s medium (DMEM, Thermo Fisher Scientific,
Waltham, MA) with 10% fetal bovine serum (FBS, Thermo
Fisher Scientific) and 4 mM L-glutamine at 37 °C, in 5% CO2, in
525 cm2 three-layer tissue culture flasks to 80–90% confluence.
Transfections were carried out using 180 g of plasmid DNA
and 450 l of Lipofectamine 2000 (Thermo Fisher Scientific)
reagent in 120ml of medium. After 16–20 h, cells were washed
and covered with 120 ml of Opti-MEM medium (Thermo
Fisher Scientific). Conditionedmedia were harvested after 48 h
incubation, replaced with 120 ml of fresh Opti-MEM, and har-
vested again at 96 h.His-tagged proenzymeswere purified from
240 ml of conditioned media using nickel affinity chromatog-
raphy on a 5-ml Ni-NTA Superflow Cartridge (number 30760,
Qiagen, Valencia, CA), with the exception of proCELA2A,
which was purified from 720 ml of media on a 1-ml Ni-NTA
cartridge (number 30721, Qiagen). The nickel column was
equilibrated with buffer NPI-20 (50 mM NaH2PO4, 300 mM
NaCl, 20mM imidazole (pH 8.0)) and themediumwas loaded at
a flow rate of 4 ml/min using a loading pump. After the column
was washed with NPI-20, zymogens were eluted with buffer
NPI-250 (50 mM NaH2PO4, 300 mM NaCl, 250 mM imidazole
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(pH 8.0)) at a flow rate of 2 ml/min and 5-ml fractions were
collected. When using the 1-ml Ni-NTA cartridge, the elution
rate was 1 ml/min and 1-ml fractions were collected. Aliquots
(25–50 l) of the fractions were analyzed by SDS-PAGE and
fractions with the highest zymogen concentration were pooled
(typically two fractions, 10 ml total volume) and dialyzed in a
8–10-kDa molecular mass cut off (MWCO) dialysis device
(Spectra/Por Float-A-Lyzer G2 Dialysis Device, number
G235055, 5 ml, Spectrum Labs, Rancho Dominguez, CA) for
36 h against two or three changes of 2–3 liters of 0.1 M Na-
HEPES (pH 8.0), 150mMNaCl (proCELA3A and proCELA3B),
or 0.1MTris-HCl (pH8.0), 100mMNaCl (proCELA2A). Finally,
the dialyzed zymogens were concentrated to a volume of 1–3
ml by centrifugation at 1500 g in a 10-kDa MWCOVivaspin
concentrator.
Non-tagged procarboxypeptidases were purified by anion-
exchange chromatography. Conditioned media (240 ml) were
first dialyzed against 20 mM Tris-HCl (pH 8.0) and loaded
directly onto a MonoQ 5/50 GL column (GE Healthcare Life
Sciences) connected to an Äkta Pure chromatography system
(GEHealthcare Life Sciences). The columnwas developed with
a NaCl gradient (0–0.5 M) over 30 min at a flow rate of 1
ml/min. Fractions (1 ml) were collected and analyzed by SDS-
PAGE and Coomassie Blue staining. The purest fractions
(90%) were used for experiments without further concentra-
tion. The fractions contained 200 mM NaCl, which became
negligible at the dilutions used for the experiments.
Concentration Determination of Zymogen Preparations—
Concentrations of purified proenzyme solutions were esti-
mated from their ultraviolet (UV) absorbance at 280 nm, using
the following extinction coefficients (in M1 cm1 units) calcu-
lated with the web-based ProtParam tool: proCELA2A 73,505;
proCELA3A 76,025; proCELA3B 74,535; proCELA3B mutant
W79R, and triple mutant S77R,S78D,W79L 69,035; proCPA1
72,435; proCPA2 66,600. Typical proelastase preparationswere
in the 2–10 M concentration range, whereas proCPA prepa-
rations were 20–35 M. Before equilibrium binding assays,
proCELA3B was titrated against proCPA1 and proCPA2 to
ensure “self-consistent” concentrations. The titration experi-
ments followed the protocol of the binding assay described
below except proCPA concentrations were fixed at 1 M and
proCELA3B was varied between 0 and 1 M.
Qualitative Binding Assays—To screen for possible binding
partners among pancreatic protease zymogens, typically 10–15
ml of conditioned medium containing a given His-tagged pro-
leastase or chymotrypsinogen was mixed with 5 ml of condi-
tioned medium with a non-tagged procarboxypeptidase. After
1 h incubation at 22 °C, the mixture was loaded onto a Bio-Rad
polyprep chromatography column containing 0.5 ml of packed
Ni-NTA Superflow resin (number 30410, Qiagen), pre-equili-
brated with NPI-20 buffer. The column was washed with 10 ml
of NPI-20 and eluted with 2.5 ml of NPI-250 buffer. Fractions
(0.5ml) were collected and 150l of each was precipitated with
10% trichloroacetic acid (final concentration) and analyzed by
15% SDS-PAGE and Coomassie Blue staining. Co-elution of
non-tagged procarboxypeptidases with His-tagged proelasta-
ses indicated binding, whereas in the absence of binding pro-
carboxypeptidases were recovered in the flow-through. In con-
trol experiments we found that none of the non-tagged
procarboxypeptidases bound nonspecifically to the nickel col-
umn. Although not directly relevant to the experiments pre-
sented, non-tagged forms of proelastases and chymotrypsino-
gens were also tested for nonspecific adsorption to the nickel
column and proCELA3A was found to exhibit some binding,
presumably due to His residues located at its N and C termini.
This property did not interferewith our binding assays inwhich
His-tagged proCELA3A was used.
Equilibrium Binding Assays—Binding of proelastases to
human procarboxypeptidases was characterized by determin-
ing theKD value of the reaction in equilibrium. Procarboxypep-
tidases at a fixed concentration (proCPA1 250 nM, proCPA2
100 nM) were incubated with increasing concentrations of His-
tagged proelastases (typically 0–500 or 0–1500 nM, as indi-
cated) in the presence of Ni-NTA Superflow resin. Before use,
the Ni-NTA resin beads were washed twice and re-suspended
in Tris-HCl (pH 8.0), 150 mMNaCl, and 0.05% Tween 20. Typ-
ically, 40 l of beads were used per 100 l of the final reaction
volume, which was found in preliminary experiments to
remove His-tagged proelastases completely in the 0–500 nM
concentration range. In the experiments where the proelastase
concentration range was 0–1500 nM, beads were increased to
75l in 150l of reaction volume. Incubations were performed
in 0.1 M Tris-HCl (pH 8.0), 150 mM NaCl, and 0.05% Tween 20
(final concentrations) at 22 °C with gentle manual shaking. In
preliminary experiments using 15 min, 1- and 16-h incubation
times we found no difference in binding, indicating that equi-
librium was reached rapidly. Therefore, we routinely used
15-min incubation times after which the nickel beads contain-
ing the bound complexes were removed by centrifugation at
1000 rpm for 1 min. The free (unbound) proCPA in the super-
natant was activated with 50 nM human cationic trypsin and
25–50 nM human CTRC (final concentrations) for 30 min at
37 °C and carboxypeptidase activity was measured from 10 to
30 l of supernatant as described below. Residual CPA activi-
ties were converted to concentrations using the activity of the
proCPA samples incubated in the absence of proleastases as the
100% reference value. The free proCPAconcentrationwas plot-
ted as a function of the total proelastase concentration and the
experimental points were fitted with the following equation:
y  E  (E  x  K-sqrt((E  x  K)2-4Ex))/2, where the
independent variable x represents the total proelastase concen-
tration, the dependent variable y is the free proCPA concentra-
tion in equilibrium; K is KD and E designates the total proCPA
concentration; sqrt, square root function.
Measurement of Carboxypeptidase Activity—Enzymatic
activity of CPA1 and CPA2 were determined using the N-[4-
methoxyphenylazoformyl]-L-phenylalanine substrate (number
M-2245, Bachem, Torrance, CA) at 60 M final concentration
in 100 or 200 l final volume (2, 6, 50, 51). Samples were sup-
plemented with assay buffer (0.1 M Tris-HCl (pH 8.0), 1 mM
CaCl2, 0.05%Tween 20) to 90 or 180l volume and the reaction
was started by adding 10 or 20 l of 600 M substrate. The
decrease in absorbance was followed at 350 nm for 5 min in a
SPECTRAmax Plus 384 microplate reader (Molecular Devices,
Sunnyvale, CA). Rates of substrate cleavage were calculated
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from fits to the linear portions of the curves and expressed in
mOD/min units.
Experimental Uncertainty and Reproducibility—Qualitative
binding experiments were carried out from at least two inde-
pendent transfections; representative gels are shown. Quanti-
tative binding experiments were performed in three technical
replicates and average values with S.E. were plotted. The data
points were fitted globally and the error of the fit was indicated.
Author Contributions—A. S., C. P., and M. B. designed and per-
formed experiments, analyzed data, prepared figures for publication,
and approved the final version of themanuscript. M. S. T. andH. W.
designed the project and analyzed data. M. S. T. wrote the
manuscript.
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